Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer

Pelvic and Aortic-cava Lymphadenectomy Randomized Phase III for Advanced Ovarian Cancer

Status

Suspended

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01218490

Acronym

CARACO

Enrollment

450

Registered

2010-10-11

Start date

2008-12-09

Completion date

2026-05-31

Last updated

2019-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

surgery, ovarian cancer, lymphadectomy

Brief summary

It is a multicenter randomized trial of superior cleaning compared the absence of dissection in stage III patients with optimal surgical resection without retroperitoneal lymph node palpable.

Interventions

PROCEDUREovarian cancer surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age\> 18 years * Karnofsky\> 80, or ASA I-II * Primary ovarian adenocarcinoma, or primitive peritoneal * No retroperitoneal lymph node\> 2cm (CT; MRI) * Complete surgical staging * Stage III-IV FIGO classification * Indication of systemic chemotherapy before surgery or post surgery

Exclusion criteria

* Non Invasive Cancer * non-epithelial or borderline cancer * Pregnancy * Previous pelvic lymphadenectomy or aortic-cava for a disease other than ovarian cancer * Contraindication to Platinum and Paclitaxel * Borderline Ovarian Tumor * tumor recurrence * Incomplete surgery, resectable lesion, Surgery sub optimal (R\> 1cm)

Design outcomes

Primary

Measure	Time frame
survival with out recurrence	5 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026